Is low dose hydroxyurea the solution to the global epidemic of sickle cell disease?
Pediatr Blood Cancer
.
2015 Jun;62(6):929-30.
doi: 10.1002/pbc.25471.
Epub 2015 Mar 8.
Author
John J Strouse
1
Affiliation
1
Department of Pediatrics, Division of Pediatric Hematology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Medicine, Division of Hematology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
PMID:
25755219
PMCID:
PMC4405448
DOI:
10.1002/pbc.25471
No abstract available
Publication types
Research Support, N.I.H., Extramural
MeSH terms
Adult
Anemia, Sickle Cell / drug therapy*
Anemia, Sickle Cell / epidemiology
Child
Humans
Hydroxyurea / adverse effects
Hydroxyurea / therapeutic use*
Substances
Hydroxyurea
Grants and funding
R34 HL108756/HL/NHLBI NIH HHS/United States
1R34HL108756-01/HL/NHLBI NIH HHS/United States